Ubs Group Ag Bellus Health Inc. Transaction History

Ubs Group Ag

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$7.14 - $8.53 $17,200 - $20,548	2,409 Added 4.31%	58,295 $419,000
Q4 2022 Feb 08, 2023	SELL	$8.22 - $10.76 $11,803 - $15,451	-1,436 Reduced 2.51%	55,886 $459,000
Q3 2022 Nov 10, 2022	BUY	$8.95 - $12.0 $513,031 - $687,864	57,322 New	57,322 $605,000
Q1 2022 May 16, 2022	SELL	$5.56 - $7.99 $35,050 - $50,368	-6,304 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $21,976 - $34,677	4,178 Added 196.52%	6,304 $51,000
Q3 2021 Nov 15, 2021	SELL	$2.7 - $6.64 $31,924 - $78,511	-11,824 Reduced 84.76%	2,126 $13,000
Q2 2021 Aug 13, 2021	BUY	$3.11 - $4.61 $37,030 - $54,891	11,907 Added 582.82%	13,950 $43,000
Q1 2021 May 12, 2021	SELL	$3.03 - $4.58 $6,556 - $9,911	-2,164 Reduced 51.44%	2,043 $8,000
Q4 2020 Feb 11, 2021	BUY	$2.27 - $3.3 $6,984 - $10,154	3,077 Added 272.3%	4,207 $13,000
Q3 2020 Nov 12, 2020	BUY	$2.14 - $12.02 $269 - $1,514	126 Added 12.55%	1,130 $3,000
Q2 2020 Jul 31, 2020	SELL	$8.88 - $11.15 $1,998 - $2,508	-225 Reduced 18.31%	1,004 $10,000
Q1 2020 May 01, 2020	BUY	$5.77 - $10.85 $1,367 - $2,571	237 Added 23.89%	1,229 $12,000
Q4 2019 Feb 14, 2020	SELL	$5.76 - $7.6 $5,662 - $7,470	-983 Reduced 49.77%	992 $8,000
Q3 2019 Nov 14, 2019	BUY	$6.24 - $8.84 $12,324 - $17,459	1,975 New	1,975 $13,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.